Patents by Inventor Marieke Griffioen

Marieke Griffioen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TREATMENT OF HAEMATOLOGICAL MALIGNANCIES
    Publication number: 20220305102
    Abstract: Novel nucleic acid sequences, vectors, modified cells, peptides and pharmaceutical compositions are provided that are useful in the treatment of human subjects having a ?NPM1 positive haematological malignancy. Corresponding methods and uses are also provided.
    Type: Application
    Filed: May 13, 2022
    Publication date: September 29, 2022
    Applicant: ACADEMISCH ZIEKENHUIS LEIDEN (H.O.D.N. LEIDS UNIVERSITAIR MEDISCH CENTRUM)
    Inventors: Marieke GRIFFIOEN, J. H. Frederik FALKENBURG
  • Treatment of haematological malignancies
    Patent number: 11352389
    Abstract: Novel nucleic acid sequences, vectors, modified cells, peptides and pharmaceutical compositions are provided that are useful in the treatment of human subjects having a ?NPM1 positive haematological malignancy. Corresponding methods and uses are also provided.
    Type: Grant
    Filed: June 28, 2018
    Date of Patent: June 7, 2022
    Assignee: Academisch Ziekenhuis Leiden (h.o.d.n. Leids Universitair Medisch Centrum)
    Inventors: Marieke Griffioen, J. H. Frederik Falkenburg
  • TREATMENT OF HAEMATOLOGICAL MALIGNANCIES
    Publication number: 20200123200
    Abstract: Novel nucleic acid sequences, vectors, modified cells, peptides and pharmaceutical compositions are provided that are useful in the treatment of human subjects having a ?NPM 1 positive haematological malignancy. Corresponding methods and uses are also provided.
    Type: Application
    Filed: June 28, 2018
    Publication date: April 23, 2020
    Inventors: Marieke GRIFFIOEN, J. H. Frederik FALKENBURG
  • PRAME derived peptides and immunogenic compositions comprising these
    Patent number: 10450356
    Abstract: The invention relates to a peptide having a length of no more than 100 amino acids and comprising at least 19 contiguous amino acids from the amino acid sequence of the human PRAME protein, wherein the peptide comprises at least one HLA class II epitope and at least one HLA class I epitope from the amino acid sequence of the human PRAME protein and to its use as such or in a composition as a medicament for the treatment and/or prevention of cancer.
    Type: Grant
    Filed: August 4, 2016
    Date of Patent: October 22, 2019
    Assignee: ACADEMISCH ZIEKENHUIS LEIDEN H.O.D.N. LUMC
    Inventors: Jan Kessler, Marieke Griffioen, Cornelis Johannes Maria Melief, Jan Wouter Drijfhout
  • PRAME DERIVED PEPTIDES AND IMMUNOGENIC COMPOSITIONS COMPRISING THESE
    Publication number: 20160333065
    Abstract: The invention relates to a peptide having a length of no more than 100 amino acids and comprising at least 19 contiguous amino acids from the amino acid sequence of the human PRAME protein, wherein the peptide comprises at least one HLA class II epitope and at least one HLA class I epitope from the amino acid sequence of the human PRAME protein and to its use as such or in a composition as a medicament for the treatment and/or prevention of cancer.
    Type: Application
    Filed: August 4, 2016
    Publication date: November 17, 2016
    Applicant: Academisch Ziekenhuis Leiden H.O.D.N. LUMC
    Inventors: Jan KESSLER, Marieke GRIFFIOEN, Cornelis Johannes Maria MELIEF, Jan Wouter DRIJFHOUT
  • Prame derived peptides and immunogenic compositions comprising these
    Patent number: 9441025
    Abstract: The invention relates to a peptide having a length of no more than 100 amino acids and comprising at least 19 contiguous amino acids from the amino acid sequence of the human PRAME protein, wherein the peptide comprises at least one HLA class II epitope and at least one HLA class I epitope from the amino acid sequence of the human PRAME protein and to its use as such or in a composition as a medicament for the treatment and/or prevention of cancer.
    Type: Grant
    Filed: July 18, 2013
    Date of Patent: September 13, 2016
    Assignee: Academisch Ziekenhuis Leiden H.O.D.N. LUMC
    Inventors: Jan Kessler, Marieke Griffioen, Cornelis Johannes Maria Melief, Jan Wouter Drijfhout
  • Prame derived peptides and immunogenic compositions comprising these
    Publication number: 20140348862
    Abstract: The invention relates to a peptide having a length of no more than 100 amino acids and comprising at least 19 contiguous amino acids from the amino acid sequence of the human PRAME protein, wherein the peptide comprises at least one HLA class II epitope and at least one HLA class I epitope from the amino acid sequence of the human PRAME protein and to its use as such or in a composition as a medicament for the treatment and/or prevention of cancer.
    Type: Application
    Filed: July 18, 2013
    Publication date: November 27, 2014
    Applicant: Academisch Ziekenhuis Leiden h.o.d.n. LUMC
    Inventors: Jan Kessler, Marieke Griffioen, Cornelis Johannes Maria Melief, Jan Wouter Drijfhout
  • PRAME derived peptides and immunogenic compositions comprising these
    Patent number: 8492514
    Abstract: The invention relates to a peptide having a length of no more than 100 amino acids and comprising at least 19 contiguous amino acids from the amino acid sequence of the human PRAME protein, wherein the peptide comprises at least one HLA class II epitope and at least one HLA class I epitope from the amino acid sequence of the human PRAME protein and to its use as such or in a composition as a medicament for the treatment and/or prevention of cancer.
    Type: Grant
    Filed: September 24, 2009
    Date of Patent: July 23, 2013
    Assignee: Academisch Ziekenhuis Leiden h.o.d.n. LUMC
    Inventors: Jan Kessler, Marieke Griffioen, Cornelis Johannes Melief, Jan Wouter Drijfhout
  • Prame derived peptides and immunogenic compositions comprising these
    Publication number: 20100120683
    Abstract: The invention relates to a peptide having a length of no more than 100 amino acids and comprising at least 19 contiguous amino acids from the amino acid sequence of the human PRAME protein, wherein the peptide comprises at least one HLA class II epitope and at least one HLA class I epitope from the amino acid sequence of the human PRAME protein and to its use as such or in a composition as a medicament for the treatment and/or prevention of cancer.
    Type: Application
    Filed: September 24, 2009
    Publication date: May 13, 2010
    Applicant: Academisch Ziekenhuis Leiden h.o.d.n. LUCM
    Inventors: Jan Kessler, Marieke Griffioen, Cornelis Johannes Maria Melief, Jan Wouter Drijfhout